Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

Power BI now sits at the center of practical analytics. The correct course should teach reliable modeling, clear DAX ...